TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35511950

Group type: EXPERIMENTAL
Intervention: VITAL model (viral load-triggered, participant's preference-informed, eHealth-supported, automated differentiated service delivery model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VITAL model
Number of subjects: 0
Study: 32050042

Group type: EXPERIMENTAL
Intervention: NLR >4.26
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count >5800/µL
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Relative neutrophil count >69.7%
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Relative lymphocyte count ≤17.5%
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Absolute monocytes >810/µL
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Absolute eosinophils ≤200/µL
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Relative monocytes >6.6%
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Relative eosinophils ≤2.7%
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Relative basophils ≤0.6%
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Combined score including absolute levels of neutrophils, lymphocytes, monocytes and eosinophils
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Risk score of 3–4
Number of subjects: 1412
Study: 34967224

Group type: EXPERIMENTAL
Intervention: Multidisciplinary group‐based pain management programme (standard care plus intervention)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard care (examination by a rheumatologist and/or physiotherapist)
Number of subjects: 136
Study: 36153477

Group type: EXPERIMENTAL
Intervention: Handgrip strength measurement
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chewing function measurement
Number of subjects: 120
Study: 33068037

Group type: EXPERIMENTAL
Intervention: Omaveloxolone (150mg per day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 34291993

Group type: EXPERIMENTAL
Intervention: Nicotine education messaging (n = 362)
Number of subjects: 543

Group type: COMPARATOR
Intervention: No message control (n = 181)
Number of subjects: 543
Study: 34200137

Group type: EXPERIMENTAL
Intervention: Pain neurophysiology education + Therapeutic exercise (PNE + TE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Therapeutic exercise (TE)
Number of subjects: 32
Study: 36368972

Group type: EXPERIMENTAL
Intervention: PEEK healing abutments
Number of subjects: 11

Group type: COMPARATOR
Intervention: Titanium healing abutments
Number of subjects: 11
Study: 33494785

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 15000

Group type: COMPARATOR
Intervention: 325 mg aspirin
Number of subjects: 15000
Study: 32532483

Group type: EXPERIMENTAL
Intervention: Stopping GDM (SGDM) intervention
Number of subjects: 11
Study: 36227598

Group type: EXPERIMENTAL
Intervention: ADHD diagnosis
Number of subjects: 393
Study: 33782738

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 32248760

Group type: EXPERIMENTAL
Intervention: SISTAS intervention (dietary and physical activity intervention)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 337
Study: 36243174

Group type: EXPERIMENTAL
Intervention: Eye-tracking analysis
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional observations
Number of subjects: 49
Study: 34441791

Group type: EXPERIMENTAL
Intervention: Neck exercise training (NET)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined training (NET + SST)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 35334957

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Adherence Screener (MEDAS)
Number of subjects: 0
Study: 35084905

Group type: EXPERIMENTAL
Intervention: Reveal condition (confidence rating after lineup rejection)
Number of subjects: 3346

Group type: COMPARATOR
Intervention: Standard simultaneous lineup (control condition)
Number of subjects: 3346
Study: 33932193

Group type: EXPERIMENTAL
Intervention: Endophytic fungi selected for L‐asparaginase (L‐ASNase) production test (20 isolates).
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Phyllosticta catimbauensis URM 7672 for partial optimisation of L‐ASNase production.
Number of subjects: 66
Study: 33894049

Group type: EXPERIMENTAL
Intervention: Video consent
Number of subjects: 30

Group type: COMPARATOR
Intervention: Written consent
Number of subjects: 30
Study: 33206039

Group type: EXPERIMENTAL
Intervention: Precision clinical trial framework including treatment‐targeted enrichment, adaptive treatments, and precise measurement.
Number of subjects: 0
Study: 616741616

Group type: EXPERIMENTAL
Intervention: Cross-sectional area (CSA) of lumbar muscles
Number of subjects: 209

Group type: COMPARATOR
Intervention: Demographic and psychosocial variables
Number of subjects: 209
Study: 34189995

Group type: EXPERIMENTAL
Intervention: PRC-063 (Extended-Release Methylphenidate)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 34078317

Group type: EXPERIMENTAL
Intervention: PEG‐modified‐rhG‐CSF
Number of subjects: 60
Study: 32100161

Group type: EXPERIMENTAL
Intervention: In-plane technique (n=31)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Out-of-plane technique (n=34)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: In-plane technique
Number of subjects: 65

Group type: COMPARATOR
Intervention: Out-of-plane technique
Number of subjects: 65
Study: 33098169

Group type: EXPERIMENTAL
Intervention: Lobaplatin (LBP) with paclitaxel (PTX)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Carboplatin (CBP) with paclitaxel (PTX)
Number of subjects: 120
Study: 32570811

Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein supplement (leucine 3 g, protein mixture 17 g, vitamin D 800 IU, calcium 300 mg, fat 1.1 g, carbohydrate 2.5 g)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate supplement
Number of subjects: 120
Study: 32190975

Group type: EXPERIMENTAL
Intervention: Conservative care program including condition education, group exercise, and dietary intervention
Number of subjects: 96
Study: 35243875

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1112
Study: 33961817

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 32705925

Group type: EXPERIMENTAL
Intervention: Curcumin (combined with LipiSperse)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 36173236

Group type: EXPERIMENTAL
Intervention: Bionic Pancreas (BP) with insulin aspart or insulin lispro (N=107)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard-of-Care (SC) control group (N=54)
Number of subjects: 161
Study: 35754023

Group type: EXPERIMENTAL
Intervention: TKM-based health promotion program
Number of subjects: 309

Group type: COMPARATOR
Intervention: Basic services of CCCs
Number of subjects: 309
Study: 32014812

Group type: EXPERIMENTAL
Intervention: Ramucirumab with paclitaxel
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Baseline biomarkers (CRP, HGF, ICAM-3, IL-8, SAA, VCAM-1)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: VEGF-D and PlGF
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Other markers
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Biomarker predictive analysis
Number of subjects: 637
Study: 36143882

Group type: EXPERIMENTAL
Intervention: in motion Nd:YAG laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: traditional Nd:YAG laser
Number of subjects: 40
Study: 34847963

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 84
Study: 32812039

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir plus standard care
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 66
Study: 36229120

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 80
Study: 34343296

Group type: EXPERIMENTAL
Intervention: Metformin followed by glipizide and then insulin glargine on failure to achieve HbA1c < 6.5%
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Initial triple therapy with metformin/pioglitazone/exenatide
Number of subjects: 261
Study: 33778929

Group type: EXPERIMENTAL
Intervention: Etrolizumab 105 mg by Autoinjector (AI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Etrolizumab 105 mg by Prefilled Syringe with Needle Safety Device (PFS‐NSD)
Number of subjects: 180
Study: 32630752

Group type: EXPERIMENTAL
Intervention: Smartphone accelerometer and gyroscope data analysis using the modified movelet method
Number of subjects: 4
Study: 34662553

Group type: EXPERIMENTAL
Intervention: 21-gauge cannulas (group 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 18-gauge cannulas (group 2)
Number of subjects: 33
Study: 34974502

Group type: EXPERIMENTAL
Intervention: 6 g of l-Citrulline (CIT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study: 35973515

Group type: EXPERIMENTAL
Intervention: Subscapularis tenotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 100
Study: 32430370

Group type: EXPERIMENTAL
Intervention: Higher burnout scores (25%)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Lower burnout scores
Number of subjects: 506
Study: 36079823

Group type: EXPERIMENTAL
Intervention: Nutritive intervention (meal rich in protein and carbohydrates) after strength training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control training (without nutritive intervention)
Number of subjects: 0
Study: 36213951

Group type: EXPERIMENTAL
Intervention: Posts before the pandemic featuring at least one food item
Number of subjects: 304

Group type: COMPARATOR
Intervention: Posts during the pandemic featuring at least one food item
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Posts before the pandemic featuring ultra-processed foods
Number of subjects: 304

Group type: COMPARATOR
Intervention: Posts during the pandemic featuring ultra-processed foods
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Marketing strategies used before the pandemic
Number of subjects: 304

Group type: COMPARATOR
Intervention: Marketing strategies used during the pandemic
Number of subjects: 304

Group type: COMPARATOR
Intervention: Most frequent COVID-19 marketing strategies during the pandemic
Number of subjects: 304
Study: 32556749

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 20
Study: 32228789

Group type: EXPERIMENTAL
Intervention: Nutritional counseling and lipid-based nutrient supplementation (LNS)
Number of subjects: 6960

Group type: EXPERIMENTAL
Intervention: Combined WSHN (water, sanitation, handwashing, and nutrition)
Number of subjects: 6960

Group type: COMPARATOR
Intervention: Water, sanitation, and handwashing interventions with behavior change messaging
Number of subjects: 6960
Study: 33904647

Group type: EXPERIMENTAL
Intervention: Innocor (high airflow resistance)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oxycon Pro (low airflow resistance)
Number of subjects: 16
Study: 32332608

Group type: EXPERIMENTAL
Intervention: Head-lift position
Number of subjects: 124

Group type: COMPARATOR
Intervention: Neutral-head position
Number of subjects: 124
Study: 33301383

Group type: EXPERIMENTAL
Intervention: Supplemented group (n=9) ingested 30g of CHO during exercise and 40g of CHO immediately after each training session.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-supplemented group (n=9) consumed a non-caloric placebo during exercise.
Number of subjects: 18
Study: 35894877

Group type: EXPERIMENTAL
Intervention: Speed endurance training (SET)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 17
Study: 33582575

Group type: EXPERIMENTAL
Intervention: Opioid receptor antagonist naltrexone (NAL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Running (RUN)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Walking (WALK)
Number of subjects: 63
Study: 32821284

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RES)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined Exercise (COM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Session
Number of subjects: 20
Study: 34381173

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 33352487

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Sublingual buprenorphine-naloxone (BUP-NX)
Number of subjects: 474
Study: 34473938

Group type: EXPERIMENTAL
Intervention: Increased tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Increased vector magnitude counts
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Most active phenotype
Number of subjects: 55
Study: 33693835

Group type: EXPERIMENTAL
Intervention: Dietary intervention (280 g whole blueberries and 12 g soluble fiber per day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard prenatal care (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 33012729

Group type: EXPERIMENTAL
Intervention: Continuous haemoperfusion (CHP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine haemoperfusion (HP)
Number of subjects: 82
Study: 36051241

Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35077507

Group type: EXPERIMENTAL
Intervention: 8-week caregiver-mediated exercises intervention (N = 63; 31 Australian and 32 Dutch)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (N = 66; 32 Australian and 34 Dutch)
Number of subjects: 129
Study: 33007286

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35596691

Group type: EXPERIMENTAL
Intervention: Batched stepped wedge design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard stepped wedge design
Number of subjects: 0
Study: 33494380

Group type: EXPERIMENTAL
Intervention: Transconjunctival injection of BTX‐A (3 units); n = 15, 25 eyes
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Transcutaneous injection of BTX‐A (3 units); n = 16, 28 eyes
Number of subjects: 31
Study: 32955964

Group type: EXPERIMENTAL
Intervention: Herbarium mixture (G. ulmifolia/T. stans) 400 mg before each meal for 90 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 40
Study: 33066862

Group type: EXPERIMENTAL
Intervention: Nardostachys jatamansi (3 g total, 1 capsule 3 times a day for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 36299870

Group type: EXPERIMENTAL
Intervention: Combined topical airway anesthesia induction strategy (aerosol inhalation airway anesthesia, subglottic airway anesthesia, and low-dose intravenous anesthetics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional induction group (high-dose intravenous anesthetics)
Number of subjects: 0
Study: 33388491

Group type: EXPERIMENTAL
Intervention: EVE (leuprorelin + LET + EVE)
Number of subjects: 137

Group type: COMPARATOR
Intervention: LET (leuprorelin + LET)
Number of subjects: 137
Study: 35963531

Group type: EXPERIMENTAL
Intervention: Clinician-facing Jumpstart (Trial 1)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Bi-directional Jumpstart (Trial 2)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Usual care (Trial 1)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Usual care (Trial 2)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Clinician-facing Jumpstart (Trial 2)
Number of subjects: 2600
Study: 34283740

Group type: EXPERIMENTAL
Intervention: Worked Example followed by Problem-Solving (WE-PS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Worked Example followed by Worked Example (WE-WE)
Number of subjects: 79
Study: 32393559

Group type: EXPERIMENTAL
Intervention: Intra-articular hypertonic dextrose prolotherapy (DPT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal saline (NS) injection
Number of subjects: 76
Study: 36329428

Group type: EXPERIMENTAL
Intervention: PRP + Artz (2.5 ml, 10 mg/ml HA followed by 3 ml PRP)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PRP + HYAJOINT Plus (3 ml, 20 mg/ml cross‐linked HA followed by 3 ml PRP)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 99
Study: 35153177

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Indomethacin + IV saline hydration
Number of subjects: 120
Study: 32250562

Group type: COMPARATOR
Intervention: Fixed multibrackets appliance (MB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Removable clear aligners (CA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Removable positioner (RP)
Number of subjects: 90
Study: 37616308

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 56
Study: 34629067

Group type: EXPERIMENTAL
Intervention: 50% calorie-restricted and ketogenic diet combined with aerobic exercise during intravenous chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 32769919

Group type: EXPERIMENTAL
Intervention: LED photobiomodulation therapy 3 times a week for 2 weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sham therapy 3 times a week for 2 weeks
Number of subjects: 148
Study: 35283313

Group type: EXPERIMENTAL
Intervention: BTN162b2
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: mRNA‐1273
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: ChAdOx1 followed by an mRNA vaccine
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: Spike‐ACE2‐receptor‐blocking antibodies
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 6544
Study: 35549365

Group type: EXPERIMENTAL
Intervention: Relational Savoring (RS)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Personal Savoring (PS)
Number of subjects: 164
Study: 32924226

Group type: EXPERIMENTAL
Intervention: Conventional impressions
Number of subjects: 15

Group type: COMPARATOR
Intervention: IOS groups (CS3600, i500, EZIS PO)
Number of subjects: 15
Study: 32756845

Group type: EXPERIMENTAL
Intervention: MS/2 medium supplemented with 100 mg L‐1 of cysteine, 0.5 mg L‐1 of gibberellic acid (AG3) and 30 g L‐1 of sucrose
Number of subjects: 60
Study: 34812713

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (fluoxetine)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and/or pharmacological treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Baseline impulsivity
Number of subjects: 108
Study: 33401168

Group type: EXPERIMENTAL
Intervention: Multivariate LSTM approach
Number of subjects: 400000000

Group type: EXPERIMENTAL
Intervention: Recursive multi-step LSTM algorithm
Number of subjects: 400000000

Group type: COMPARATOR
Intervention: Simple frequency monitoring approach
Number of subjects: 400000000
Study: 33139781

Group type: EXPERIMENTAL
Intervention: Presence of anti-Toxoplasma gondii antibodies in MS patients
Number of subjects: 129

Group type: COMPARATOR
Intervention: Presence of anti-Toxoplasma gondii antibodies in controls
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: History of mononucleosis
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: High educational level
Number of subjects: 129
Study: 35499744

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (808 nm, 36 J for 360 s) under the tongue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photobiomodulation over the radial artery
Number of subjects: 0
Study: 35875890

Group type: EXPERIMENTAL
Intervention: Vutrisiran 25 mg every 3 months (Q3M)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Patisiran 0.3 mg/kg every 3 weeks (Q3W)
Number of subjects: 164
Study: 32167389

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study: 35703711

Group type: EXPERIMENTAL
Intervention: Radiographic method for determining working length
Number of subjects: 64

Group type: COMPARATOR
Intervention: Electronic apex locator for determining working length
Number of subjects: 64
Study: 32881639

Group type: EXPERIMENTAL
Intervention: Post-discharge phone calls from a navigator to review the recommended treatment plan and address barriers to engagement on days 3, 7, 14, and 21
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (no post-discharge navigation)
Number of subjects: 395
Study: 32282720

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and electronic moxibustion (EM) + alpha blocker
Number of subjects: 78

Group type: COMPARATOR
Intervention: Alpha blocker
Number of subjects: 78
Study: 33336359

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) infused over 10 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS) infused over 10 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA) infused over 10 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosphenytoin (FOS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Valproic Acid (VPA)
Number of subjects: 27
Study: 33317802

Group type: EXPERIMENTAL
Intervention: Physostigmine 0.5 mg h−1 i.v. for 24 h
Number of subjects: 110
Study: 33407318

Group type: EXPERIMENTAL
Intervention: SMS messages over 4 weeks to encourage dog walking and play
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SMS messages, dog pedometer, and personalized 'dog steps' diary
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 150
Study: 32034241

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 50